1. Home
  2. BRLT vs KTTA Comparison

BRLT vs KTTA Comparison

Compare BRLT & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brilliant Earth Group Inc.

BRLT

Brilliant Earth Group Inc.

HOLD

Current Price

$1.06

Market Cap

18.9M

ML Signal

HOLD

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

HOLD

Current Price

$0.45

Market Cap

18.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRLT
KTTA
Founded
2005
2020
Country
United States
United States
Employees
N/A
5
Industry
Consumer Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.9M
18.1M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
BRLT
KTTA
Price
$1.06
$0.45
Analyst Decision
Hold
Strong Buy
Analyst Count
4
1
Target Price
$1.70
$3.00
AVG Volume (30 Days)
36.3K
332.4K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$437,483,000.00
N/A
Revenue This Year
$6.72
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.63
N/A
52 Week Low
$1.00
$0.28
52 Week High
$3.10
$2.06

Technical Indicators

Market Signals
Indicator
BRLT
KTTA
Relative Strength Index (RSI) 41.26 37.55
Support Level N/A $0.28
Resistance Level $1.25 $0.52
Average True Range (ATR) 0.08 0.04
MACD -0.01 0.00
Stochastic Oscillator 13.51 28.21

Price Performance

Historical Comparison
BRLT
KTTA

About BRLT Brilliant Earth Group Inc.

Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: